Focus Stocks
Amgen Expecting Resistance Soon?
Published on Monday, 30 August 2010 05:40 Written by Danny Miller
New York, August 30th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) closed the trading session at $52.08 near its 50 day moving average currently set at $53.68. Amgen's price action is below this important level, which makes the stock difficult to buy, as there will certainly be resistance as it approaches its 50 day.
Amgen Inc. (NASDAQ:AMGN) develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The company concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
Latest price action range, defined by a peaks and troughs algorithm places calculated support at $50.71 and calculated resistance at $56.14. These levels will be closely watched by traders, as they provide great insight into the latest price dynamics defined by Amgen shares.
Traders should evaluate their trade if they want to establish a position on Amgen given the resistance expected as the stock approaches the 50 day moving average. A trade might materialize as the stock manages to break this important level, as it could be used as support going forward, however until the break materializes buying the stock is nothing different than flipping a coin. Other levels that traders will be evaluating are the ones defined by the peak and troughs algorithm that provides great price level reference points.
Related Articles
- NASDAQ 100 Mid-day Update: Lower Top Performers: VRTX, FSLR, GILD
- Amgen near Resistance
- Is Amgen Breaking Out?
- Trading Idea - Is Amgen close to Resistance?
- Amgen Higher Ahead of Earnings
- Amgen near Key Resistance Area
- Up/Downgrades ( COP, FST, CMA, PNRA, ARW, AVT, ALTH, ACOR, AMGN, FST )
- Is Amgen Breaking Out?
- Amgen - Shares Seeking Direction
- Amgen - 52 Week High
Related Partner Headlines
- Deutsche Bank: Xgeva Not Proceeding Well for Amgen - Benzinga
- Amgen to Discuss Application for New Use of XGEVA at FDA Oncologic Drugs Advisory Committee Meeting - Benzinga
- Dendreon Rockets 17% After Critical Reveiw For Amgen's Cancer Drug - Benzinga
- Piper Jaffray Postive on Amgen After FDA Releases Briefing Documents on Xgeva - Benzinga
- FDA Skeptical of Amgen Drug Ahead of Panel - TheStreet.com
- Amgen Reaches New 52-Week High (AMGN) - TheStreet.com
- Stock Market Story: Jan. 27 - TheStreet.com
- Stocks to Watch: P&G, Ford, Starbucks - TheStreet.com
- Amgen Acquires Micromet for $1.16 Billion - TheStreet.com
- Limitations of Beta-Weighted Delta Hedging - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
-
Benzinga's Microcap Movers for Wednesday February 8, 2012 - Benzinga -
Five More Stocks ETFs Need More Of - Benzinga -
ETFs to Watch February 9, 2012 - Benzinga -
'Fast Money' Recap: Cisco's Back - TheStreet.com -
Benzinga's M&A Chatter for Wednesday February 8, 2012 - Benzinga -
Market Preview: Fearing the Inevitable Pullback - TheStreet.com -
Mike Khouw's OpenTable Inc Trade - Benzinga -
Fast Money Picks For February 9th - Benzinga
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,883.95 Trade time:4:02PM EST Value change:▲5.75 (0.04%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,349.96 Trade time:4:31PM EST Value change:▲2.91 (0.22%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,915.86 Trade time:5:16PM EST Value change:▲11.78 (0.41%)In The Wires
-
Daimler Excels in Anniversary Year 2011: Group EBIT From Ongoing Business up by 24% to Record Level of Euro 9 Billion -
Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium -
UMC Reports Sales for January 2012 -
SS&C Appoints Punit Satsangi as Managing Director of EMEA Business Development -
gategroup Seeks to Extend and Amend Credit Facilities -
Publicis Groupe: 2011 Annual Results -
VIDEO from Siemens and Synaptic Digital: US Transportation Secretary LaHood to Visit Siemens Light Rail Manufacturing Plant in Sacramento -
Comstock Mining Announces Pricing of Public Offering of Common Stock










